08.11.26 -- Unlocking Global Growth Through Strategic CDMO Partnerships

Multi-product ATMP facilities need integrated teams, flexible design, and strategic HVAC to ensure scalability, contamination control, cost efficiency, and reliable long-term performance.

Ten years of AAV producer cell line development distilled into one scientist's account, including a pivotal platform pivot. Read to understand what gene therapy manufacturing actually takes.

Animal‑free soy‑based materials provide consistent molecular weight profiles, stable mineral levels, and controlled manufacturing to ensure reliable, reproducible bioprocessing performance.

Cellular immunotherapies deliver strong clinical results, but centralized manufacturing and complex logistics limit access. Regional, standardized production can expand global patient access.

Traditional plasmid DNA manufacturing introduces biological impurities and structural variability that lower viral titers. Transitioning to cell-free synthetic DNA platforms ensures sequence fidelity.

By working with a single supplier that can handle the entire manufacturing value chain, companies can reduce risk, improve flexibility, and accelerate their time to market.

Watch to gain valuable insights into the characterization of cellular source material for the development and manufacture of cell and gene therapy-based products.

From payer negotiations and formulary expansion to real-time uptake analytics and global distribution, post-launch success depends on a commercialization partner that adapts as market conditions shift.

Synthetic DNA replaces plasmids for AAV production, cutting contaminants and variability and improving reproducibility and scalability from research to manufacturing.

Protect patient safety and ensure regulatory compliance by implementing sensitive, reliable bacterial endotoxin testing as a critical component of pharmaceutical quality assurance.

Optimizing DNA inputs is key to scaling AAV therapies; cell-free enzymatic methods can cut costs up to 22%, saving millions annually at commercial scale.

Multiplex engineering of T cells for solid tumors requires precise delivery. Emerging LNP approaches enable co-delivery of RNA and DNA, offering a safer, more scalable path beyond viral vectors.

Accurate AAV capsid ratios are critical to gene therapy efficacy. See how mass photometry delivers faster, lower-cost E/F analysis with single-particle resolution.